BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 23878932)

  • 1. Biochemical characterization of MurF from Streptococcus pneumoniae and the identification of a new MurF inhibitor through ligand-based virtual screening.
    Turk S; Hrast M; Sosic I; Barreteau H; Mengin-Lecreulx D; Blanot D; Gobec S
    Acta Chim Slov; 2013; 60(2):294-9. PubMed ID: 23878932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of second generation MurF inhibitors based on a cyanothiophene scaffold.
    Hrast M; Anderluh M; Knez D; Randall CP; Barreteau H; O'Neill AJ; Blanot D; Gobec S
    Eur J Med Chem; 2014 Feb; 73():83-96. PubMed ID: 24384549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ultraefficient affinity-based high-throughout screening process: application to bacterial cell wall biosynthesis enzyme MurF.
    Comess KM; Schurdak ME; Voorbach MJ; Coen M; Trumbull JD; Yang H; Gao L; Tang H; Cheng X; Lerner CG; McCall JO; Burns DJ; Beutel BA
    J Biomol Screen; 2006 Oct; 11(7):743-54. PubMed ID: 16973923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
    Miller JR; Herberg JT; Tomilo M; McCroskey MC; Feilmeier BJ
    Anal Biochem; 2007 Jun; 365(1):132-43. PubMed ID: 17395144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of screening assays and discovery of initial inhibitors of pneumococcal peptidoglycan deacetylase PgdA.
    Bui NK; Turk S; Buckenmaier S; Stevenson-Jones F; Zeuch B; Gobec S; Vollmer W
    Biochem Pharmacol; 2011 Jul; 82(1):43-52. PubMed ID: 21501597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
    Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of unsaturated fatty acid auxotrophs of Streptococcus pneumoniae and Streptococcus mutans.
    Altabe S; Lopez P; de Mendoza D
    J Bacteriol; 2007 Nov; 189(22):8139-44. PubMed ID: 17827283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
    Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
    J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cloning and characterization of a new antibacterial target, 3,4-dihydroxy-2-butanone-4-phosphate synthase].
    Jin L; Zhou H; Zhao S; Yang W; Niu S; Wang D
    Wei Sheng Wu Xue Bao; 2012 Nov; 52(11):1415-20. PubMed ID: 23383514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AG205, a novel agent directed against FabK of Streptococcus pneumoniae.
    Takahata S; Iida M; Osaki Y; Saito J; Kitagawa H; Ozawa T; Yoshida T; Hoshiko S
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2869-71. PubMed ID: 16870790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de Novo design.
    Khedkar SA; Malde AK; Coutinho EC
    J Chem Inf Model; 2007; 47(5):1839-46. PubMed ID: 17663541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.
    Park HS; Jung SJ; Kwak JH; Choi DR; Choi EC
    Int J Antimicrob Agents; 2010 Jul; 36(1):97-8. PubMed ID: 20403681
    [No Abstract]   [Full Text] [Related]  

  • 13. Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening.
    Turk S; Kovac A; Boniface A; Bostock JM; Chopra I; Blanot D; Gobec S
    Bioorg Med Chem; 2009 Mar; 17(5):1884-9. PubMed ID: 19223185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput Streptococcus pneumoniae transcription/translation screen.
    Pratt SD; David CA; Black-Schaefer C; Dandliker PJ; Xuei X; Warrior U; Burns DJ; Zhong P; Cao Z; Saiki AY; Lerner CG; Chovan LE; Soni NB; Nilius AM; Wagenaar FL; Merta PJ; Traphagen LM; Beutel BA
    J Biomol Screen; 2004 Feb; 9(1):3-11. PubMed ID: 15006143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae.
    Prudhomme M; Attaiech L; Sanchez G; Martin B; Claverys JP
    Science; 2006 Jul; 313(5783):89-92. PubMed ID: 16825569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
    Miguet L; Zervosen A; Gerards T; Pasha FA; Luxen A; Distèche-Nguyen M; Thomas A
    J Med Chem; 2009 Oct; 52(19):5926-36. PubMed ID: 19746934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of N-acylhydrazones as inhibitors of MurC and MurD ligases.
    Sink R; Kovac A; Tomasić T; Rupnik V; Boniface A; Bostock J; Chopra I; Blanot D; Masic LP; Gobec S; Zega A
    ChemMedChem; 2008 Sep; 3(9):1362-70. PubMed ID: 18651694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
    Davies TA; Page MG; Shang W; Andrew T; Kania M; Bush K
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2621-4. PubMed ID: 17470659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
    Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
    J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.